Stockscreener 앱 받기
38.45
3.83%
1.42
시간 외 거래:
38.44
-0.01
-0.03%
Praxis Precision Medicines Inc 주식(PRAX)의 최신 뉴스
(PRAX) Trading Report - news.stocktradersdaily.com
Deutsche Bank AG Buys 5,009 Shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - Defense World
Praxis Precision Medicines to Participate in Upcoming Conferences - GlobeNewswire
Praxis Precision Medicines to Participate in Upcoming Conferences | PRAX Stock News - GuruFocus
What is Chardan Capital’s Forecast for PRAX FY2025 Earnings? - Defense World
Dimensional Fund Advisors LP Decreases Position in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - Defense World
Northern Trust Corp Raises Stock Holdings in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - Defense World
(PRAX) Investment Report - news.stocktradersdaily.com
Piper Sandler maintains Praxis stock at $270 target, bullish stance By Investing.com - Investing.com India
Praxis Precision Medicines (NASDAQ:PRAX) Research Coverage Started at Chardan Capital - Defense World
Praxis Precision Medicines (PRAX) to Release Earnings on Monday - Defense World
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
Analytical Lens: Exploring Praxis Precision Medicines Inc (PRAX)’s Financial Story Through Ratios - DWinneX
3,008 Shares in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Bought by Envestnet Asset Management Inc. - Defense World
Wedbush Has Positive Outlook for PRAX Q2 Earnings - Defense World
This Waste Connections Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - NewsBreak: Local News & Alerts
HC Wainwright Issues Negative Forecast for PRAX Earnings - Defense World
Praxis Precision Medicines 'A Diversified Player In Epilepsy Market,' Analyst Sees Over 100% Stock Upside - Benzinga
Chardan Capital Initiates Coverage of Praxis Precision Medicines (PRAX) with Buy Recommendation - Nasdaq
Chardan Capital Initiates Coverage on PRAX with a Buy Rating | PRAX Stock News - GuruFocus
Chardan Initiates Praxis Precision Medicines at Buy With $80 Price Target - marketscreener.com
Chardan Initiates Coverage on Praxis Precision (PRAX) with Buy Rating | PRAX Stock News - GuruFocus
Analysts Issue Forecasts for PRAX Q4 Earnings - Defense World
HC Wainwright Has Bearish Forecast for PRAX FY2029 Earnings - Defense World
Praxis Precision Medicines (NASDAQ:PRAX) Given New $28.00 Price Target at Wedbush - Defense World
Analysts Offer Insights on Healthcare Companies: Cerus (CERS), Stryker (SYK) and Praxis Precision Medicines (PRAX) - The Globe and Mail
Praxis Precision Medicines (NASDAQ:PRAX) Receives “Buy” Rating from Needham & Company LLC - Defense World
Praxis Precision Medicines Highlights DEE Clinical Program Updates at Virtual Investor Event - GlobeNewswire
Praxis Precision Medicines: Advancements and Financial Outlook - TipRanks
Wedbush Adjusts Price Target for Praxis Precision Medicine (PRAX - GuruFocus
Wedbush Adjusts Price Target for Praxis Precision Medicine (PRAX) | PRAX Stock News - GuruFocus
PRAX Stock Target Increased by Baird Amid Positive Epilepsy Drug Outlook | PRAX Stock News - GuruFocus
Wedbush Lifts Price Target on Praxis Precision Medicines to $28 From $26, Keeps Underperform Rating - marketscreener.com
PRAX Unveils Progress in DEE Clinical Programs | PRAX Stock News - GuruFocus
Clinical Trial Success: Praxis's DEE Drug Cuts Seizures by 90%, Eyes $3B Market Opportunity - Stock Titan
Praxis Precision Medicine (PRAX): Buy Rating Reiterated by Needham | PRAX Stock News - GuruFocus
Praxis Precision Medicines First Quarter 2025 Earnings: US$3.29 loss per share (vs US$2.85 loss in 1Q 2024) - Yahoo
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | PRAX Stock News - GuruFocus
Praxis Precision Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - marketscreener.com
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Praxis Precision Medicines Awards 3,688 Restricted Stock Units to 5 New Non-Executive Hires - Stock Titan
Praxis Precision Medicines Provides Corporate Update and Reports - GuruFocus
PRAX Revenue Falls Short as Company Focuses on Epilepsy Portfoli - GuruFocus
PRAX Revenue Falls Short as Company Focuses on Epilepsy Portfolio | PRAX Stock News - GuruFocus
Praxis Precision Medicines, Inc. SEC 10-Q Report - TradingView
Praxis Precision Medicines Reports Significant Progress and Upcoming Milestones in Epilepsy Portfolio - Nasdaq
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2025 Financial Results - GlobeNewswire
Wells Fargo & Company MN Boosts Stake in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - Defense World
Assessing Praxis Precision Medicine: Insights From 8 Financial Analysts - Benzinga
PRAX: HC Wainwright Reiterates Buy Rating and $105 Price Target | PRAX Stock News - GuruFocus
Praxis Precision Medicines Inc (PRAX)’s Ratio Roundup: Key Metrics for Trailing Twelve Months - DWinneX
A closer look at Praxis Precision Medicines Inc (PRAX) is warranted - uspostnews.com
JPMorgan Chase & Co. Has $746,000 Stock Holdings in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - Defense World
Praxis Precision Medicines (NASDAQ:PRAX) vs. Dr. Reddy’s Laboratories (NYSE:RDY) Head to Head Comparison - Defense World
0.95%
자본화:
|
볼륨(24시간):